Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures
July 12th, 2024
Here, we describe the modified treatment methods for wasting marmoset syndrome (WMS, also known as inflammatory bowel disease (IBD)-like disease) with tranexamic acid. We also present how to administer the therapeutic agents orally, subcutaneously, and intravenously.
Our original treatment protocol for Wasting Marmoset Syndrome was definitely effective, but it imposed a heavy load on marmosets and their caregivers. In this study, we have modified the protocol to decrease both the animal physiological load and the caregiver's workload. Our protocol using the tranexamic acid has several advantages compared to steroid therapy.
It does not cause notable side effects or lead to tolerance. Additionally, subcutaneous administration is safer than intraperitoneal injection because there is no risk of injury to the abdominal organs. One of our top priorities is to determine how Wasting Marmoset Syndrome occurs.
Elucidating the mechanisms of the syndrome will lead to the prevention of it and the discovery of a cure. We wish to reduce the number of marmosets suffering from Wasting Marmoset Syndrome. Begin by administering the desired iron formulation orally to a WMS affected marmoset.
To do so, mix 0.1 milliliters of the iron formulation with a piece of sponge cake. Give the mash to the treated marmoset. For subcutaneous administration, let the animal cling to the assistant's chest or arm.
Clean the area of the animal's back with an alcohol swab. Then using a 26 gauge needle, subcutaneously inject 0.1 milliliters of 5%tranexamic acid solution into the animal's back. Next, using a 26 gauge needle, subcutaneously inject 5.0 milliliters of ringers lactate with 0.1 milliliters of a vitamin formulation.
For intravenous administration of the amino acid formulation, have the assistant hold the base of both arms to restrain the animal's upper body. Ask the assistant to hold the base of both legs with the other hand to restrain the animal's lower body while placing the thumb on the anterior side of the animal's knee to prevent it from bending. Clean the animal's calf with an alcohol swab.
Using a 27 gauge butterfly needle inject 2.0 milliliters of the amino acid formulation intravenously via the saphenous vein. Appearance of a WMS affected marmoset showed tabifaction, arched back, rough fur, and alopecia before treatment. However, no abnormal appearance was seen after treatment.
Overview
This study presents modified treatment methods for Wasting Marmoset Syndrome (WMS) using tranexamic acid. The new protocol aims to reduce the physiological burden on marmosets and the workload on caregivers.
Key Study Components
Area of Science
- Neuroscience
- Veterinary Medicine
- Pharmacology
Background
- Wasting Marmoset Syndrome is similar to inflammatory bowel disease.
- Original treatment protocols were effective but burdensome.
- Tranexamic acid offers advantages over steroid therapy.
- Understanding WMS mechanisms is crucial for prevention and cure.
Purpose of Study
- To modify treatment protocols for WMS.
- To decrease the physiological load on marmosets.
- To simplify caregiver workload.
Methods Used
- Oral administration of iron formulation mixed with sponge cake.
- Subcutaneous injection of tranexamic acid and vitamin formulation.
- Intravenous administration of amino acid formulation via saphenous vein.
- Monitoring of physical appearance before and after treatment.
Main Results
- Modified protocol reduced side effects compared to steroids.
- Subcutaneous administration proved safer than intraperitoneal injection.
- No abnormal appearance in marmosets post-treatment.
- Effective management of WMS symptoms observed.
Conclusions
- Tranexamic acid is a viable alternative for treating WMS.
- New methods enhance safety and reduce caregiver burden.
- Further research needed to fully understand WMS mechanisms.
